By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...

A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

and lifestyle changes Chronic obstructive pulmonary disease, commonly referred to as COPD, is a group of progressive lung diseases. An estimated 32 million people in the United States have COPD.

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

Certain groups of physical multimorbidity may be associated with a higher risk of subsequent depression, according to a recent study.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.